Insulet Corporation Share Price

Equities

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:00:00 24/05/2024 BST 5-day change 1st Jan Change
180.1 USD +5.43% Intraday chart for Insulet Corporation -3.84% -17.01%
Sales 2024 * 1.98B 155B Sales 2025 * 2.34B 184B Capitalization 12.61B 990B
Net income 2024 * 228M 17.9B Net income 2025 * 281M 22.06B EV / Sales 2024 * 6.59 x
Net Debt 2024 * 420M 32.95B Net Debt 2025 * 115M 9.06B EV / Sales 2025 * 5.44 x
P/E ratio 2024 *
58.6 x
P/E ratio 2025 *
47.8 x
Employees 3,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.43%
1 week-3.84%
Current month+4.73%
1 month+7.67%
3 months-2.25%
6 months-4.19%
Current year-17.01%
More quotes
1 week
170.67
Extreme 170.67
188.97
1 month
160.19
Extreme 160.19
193.30
Current year
160.19
Extreme 160.19
217.46
1 year
125.82
Extreme 125.82
298.95
3 years
125.82
Extreme 125.82
335.91
5 years
106.17
Extreme 106.165
335.91
10 years
23.94
Extreme 23.94
335.91
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 30/07/19
Founder 54 31/12/13
Chief Tech/Sci/R&D Officer 53 31/12/18
Members of the board TitleAgeSince
Director/Board Member 57 09/08/17
Chairman 59 13/08/14
Director/Board Member 64 03/02/22
More insiders
Date Price Change Volume
24/05/24 180.1 +5.43% 680,303
23/05/24 170.8 -5.68% 787,347
22/05/24 181.1 -0.94% 675,297
21/05/24 182.8 -0.73% 739,587
20/05/24 184.1 -1.67% 585,580

Delayed Quote Nasdaq, May 24, 2024 at 09:00 pm

More quotes
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (95.6%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (4.4%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). By the end of 2022, the group will have 2 production sites located in the United States and in China. The United States accounts for 72.2% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
180.1 USD
Average target price
233.5 USD
Spread / Average Target
+29.67%
Consensus